Kelly Fitzgerald, MD

Education
06/2023 - Medical Oncology fellowship, Memorial Sloan Kettering Cancer Center
06/2017 - Internal Medicine residency, UCSF
Publications

  1. Leeman JE, Shin KY, Droznin A, Catalano P, Cagney DN, Singer L, Oniyangi RD, Zhai K, Benham G, Chirmade S, Campbell J, Boyle S, Saranteas A, Williams CL, Huynh E, Han Z, Sudhyadhom A, Hu YH, Ferguson D, Singhrao K, Hsu SH, Bredfeldt J, Martin NE, Mancias JD, Mamon HJ, Van Dams R, Venkatachalam V, Tanguturi SK, Huynh MA, Fitzgerald KJ, Elhalawani H, Bitterman DS, Schoenfeld JD, Nguyen P, Haas-Kogan DA, Mak R. Stereotactic MRI Guided Adaptive Radiotherapy: a pooled analysis of a master prospective trial. Journal of the National Cancer Institute 2025. PMID: 40794880


  2. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]. European urology 2024. PMID: 39426859


  3. Zha Y, Ye Z, Zapaishchykova A, He J, Hsu SH, Leeman JE, Fitzgerald KJ, Kozono DE, Mak RH, Aerts HJWL, Kann BH. Delta radiomics to track radiation response in lung tumors receiving stereotactic magnetic resonance-guided radiotherapy. Physics and imaging in radiation oncology 2024. PMID: 39253728


  4. Shakhnazaryan N, Gima-Lange L, Desai A, Fitzgerald K, Kwon DH. Accuracy, readability, and quality of websites about metastatic renal cell carcinoma treatment. Urologic oncology 2024. PMID: 38955572


  5. Lee HY, Lee G, Ferguson D, Hsu SH, Hu YH, Huynh E, Sudhyadhom A, Williams CL, Cagney DN, Fitzgerald KJ, Kann BH, Kozono D, Leeman JE, Mak RH, Han Z. Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors. Biomedical physics & engineering express 2024. PMID: 38861951


  6. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. European urology 2024. PMID: 38782695


  7. Thor M, Fitzgerald K, Apte A, Oh JH, Iyer A, Odiase O, Nadeem S, Yorke ED, Chaft J, Wu AJ, Offin M, Simone Ii CB, Preeshagul I, Gelblum DY, Gomez D, Deasy JO, Rimner A. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2023. PMID: 37926331


  8. Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer 2023. PMID: 37864521


  9. Banla LI, Tzeng A, Baillieul JP, Kandekhar MJ, Fitzgerald KJ, LoPiccolo J, Poitras HA, Soto DE, Rotow JK, Singer L, Willers H, Kozono DE, Janne PA, Mak RH, Piotrowska Z, Keane FK, Kann BH. Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. JTO clinical and research reports 2023. PMID: 37732171


  10. Fitzgerald KN, Motzer RJ, Lee CH. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nature reviews. Urology 2022. PMID: 36369389


  11. Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. European urology 2022. PMID: 36344318


  12. Fitzgerald KN, Lee CH. Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. Journal of the National Comprehensive Cancer Network : JNCCN 2022. PMID: 35385828


  13. Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, Reznik E. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. European urology focus 2022. PMID: 35288096


  14. Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, Palomba ML. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leukemia & lymphoma 2021. PMID: 34949132


  15. Gupta A, Budhu S, Fitzgerald K, Giese R, Michel AO, Holland A, Campesato LF, van Snick J, Uyttenhove C, Ritter G, Wolchok JD, Merghoub T. Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Communications biology 2021. PMID: 34789823


  16. Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LF, De Henau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, Merghoub T. Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell reports 2021. PMID: 33440157


  17. Fitzgerald K, Simone CB. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer. Thoracic surgery clinics 2020. PMID: 32327181


  18. Fitzgerald, K and Daud, A.. J Clin Oncol Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma. 2019. PMID:


  19. Fitzgerald K, Tsai KK. Systemic therapy for advanced cutaneous squamous cell carcinoma. Seminars in cutaneous medicine and surgery 2019. PMID: 31051028


  20. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. MYC regulates the antitumor immune response through CD47 and PD-L1. Science (New York, N.Y.) 2016. PMID: 26966191


  21. Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, Brookes E, Cherry AB, Demirbas D, Tsankov AM, Zon LI, Rubin LL, Feinberg AP, Meissner A, Cowan CA, Daley GQ. A comparison of non-integrating reprogramming methods. Nature biotechnology 2014. PMID: 25437882